Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!

Contacts

• Trine Österbye

  VP Biopharma Solutions iLite Cell-based Assays Trine.Oesterbye@eurodiagnostica.com +46 40 53 76 47

• 

  Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!

  License:

  All rights reserved

  File format:

  .pdf

  more info...

Related content

• 6 December 2016 09:01

  Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

  Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

• 21 June 2016 15:29

  Announcing the launch of iLite™ VEGF Assay Ready Cells

  The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

• 30 March 2016 10:00

  New research on cell-based reporter gene iLite™ assays

  The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

• 22 November 2016 09:16

  Euro Diagnostica is now launching a TLR4 responsive cell line, strengthening the iLite™ Assay Ready Cell portfolio within inflammation.

  Toll-like receptor 4 (TLR4) plays a fundamental role in the activation of the innate immune response, which is why drug development of TLR4 antagonists is a hot topic for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis.